The analysis of nucleic acids has become an integral part of diagnostic medicine. Molecular test results are increasingly being used in conjunction with histology/morphology, Immunohistochemistry, special stains, and flow cytometry for more accurate and complete diagnostic, prognostic, disease monitoring, and therapeutic response information.

Many different types of genetic alterations have been identified in tumors, including single base mutations, insertions, deletions, and gains or losses of specific genes, chromosomal regions, and entire chromosomes. No single technology can accurately detect the wide variety of possible mutations. At ProPath, our experts are highly trained and experienced in the use and interpretation of a wide variety of molecular technologies. Our experts select technology platforms best suited for the sensitive and specific analyses of tumors. The technologies available in our state-of-the-art laboratory include cytogenetic (karyotype) analysis, fluorescence in-situ hybridization (FISH), PCR, RT-PCR, quantitative real time PCR, Sanger sequencing, pyrosequencing, transcription-mediated amplification, and others.


Kathleen M. Murphy, Ph.D.

Molecular Diagnostics